Valdivieso, M <br/><br/>
Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.  [electronic resource] 

 -  American journal of clinical oncology  Jun 1984 
 - 241-4 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0277-3732 
<br/><br/><label>Standard No.: </label>10.1097/00000421-198406000-00008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Anthraquinones--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Small Cell--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Drug Evaluation<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mitoxantrone<br/>Nausea--chemically induced<br/>Neutropenia--chemically induced<br/>Thrombocytopenia--chemically induced